Summary:
HYDERABAD, India and NANJING, China, Dec.
1, 2021 /PRNewswire/ -- Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for drug discovery and biopharmaceutical research.
Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon.
GOSTAR provides comprehensive information encompassing over 8 million compounds and contains more than 28 million SAR associated data points.
The well-structured relational database can be utilized for diverse applications across different phases of drug discovery and development and aids in target validation, hit identification, early lead Identification, and optimization.Silexon"s AI/ML platform uses both high-quality, real-world biological data and outstanding machine learning capabilities to aid in de novo drug design, drug discovery, and biopharmaceutical research through its disruptive predictive tools that help streamline the discovery and design process, thus shortening the time to market for new life-saving drugs.
Silexon focuses on innovative biomedicines with unique target product profiles for undruggable, difficult-to-drug, and novel targets in multiple therapeutic areas.